Catabolic effects and the influence on hormonal variables under treatment with Gynodian-Depot or dehydroepiandrosterone (DHEA) oenanthate.
53 patients from a mainly climacteric population were treated monthly with 200 mg dehydroepiandrosterone (DHEA) oenanthate or with 1 ampoule Gynodian-Depot. Pronounced adiposity was present in 15 of these cases. Hormonal variables were determined before the treatment and during the depot effect of the preparations in order to study the principle which supports the oestrogenic influence and any weight-reducing influence under administration of DHEA. The elimination of low-polar oestrogens increased considerably in 4 out of 13 post-menopausal cases treated with DHEA. This effect is probably indirect and presupposes intact ovaries. The incorporation of exogenous DHEA into the excretion of 17-ketosteroids and of 17-ketogenic steroids, such as those of androsterone + aethio-cholanolone, depends on the size of the initial pool inasmuch as it is higher in small initial pools than in saturated pools- the size of the pool being age-dependent. An average weight loss of greater than 1 kg/mth was observed under DHEA treatment in 7 out of 15 adipose cases. In comparison to the other 8 adipose cases, these 7 were younger and therefore also displayed higher values for 17-ketosteroids and their individual fractions. These circumstances appeared to explain why the administration of DHEA resulted in higher levels of free plasma DHEA which, in contrast to the cases without loss of weight, also resulted in an increase of renal DHEA-sulphate clearance. It was concluded from the findings that this is the explanation for the catabolic effect of exogenous DHEA. Post-menopausally increased FSH and LH fractions were markedly suppressed in about half of the determinations after Gynodian-Depot administration, the findings indicating that DHEA is probably involved in suppression of the LH fraction.
D015065:17-Hydroxycorticosteroids / Q000378:metabolism; D015068:17-Ketosteroids / Q000378:metabolism; D000328:Adult; D000728:Androgens / Q000378:metabolism; D002979:Climacteric / Q000187:drug effects*; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004967:Estrogens / Q000378:metabolism; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000728:Androgens; D004338:Drug Combinations; D004967:Estrogens; D006728:Hormones; C033624:dehydroepiandrosterone enanthate; D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; C033625:Gynodian; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone